Best payment processors for SARMs operators in 2026

SARMs sits in a stricter risk tier than peptides for payment processing. FDA has been more public about "research chemical" marketing language. Acquirers read "selective androgen receptor modulator" as a regulatory red flag regardless of the marketing. Approvals happen but the pool is narrower.

Who will not approve SARMs

Stripe, Square, Braintree, PayPal, Shopify Payments

All four aggregators explicitly prohibit research chemicals, unapproved compounds, and SARMs-adjacent language in their acceptable use policies. Operators who get through usually get closed inside 60-120 days. See our Stripe freeze playbook — same pattern applies.

Authorize.net direct

Visa's direct reseller program excludes research chemicals. You can't buy Authorize.net from Visa for SARMs processing. You can buy it through an ISO (see below).

Who will underwrite SARMs

Nutra-specialist ISOs with SARMs-friendly acquirers

This is where most domestic SARMs processing happens. The ISOs that consistently place SARMs in 2026:

• EasyPayDirect — places SARMs with acquirer partners that tolerate the vertical. Rate: 4.0-4.5% effective. Reserve: 10-15% rolling 180 days.
• Durango Merchant Services — similar placement profile. Reserve 15-20% on new accounts.
• PayKings — accepts SARMs but does heavier SKU review. Won't accept compounds with specific regulatory hot words.
• Corepay — nutra specialist with SARMs experience; rates similar to EasyPayDirect.
• High Risk Pay — broader high-risk book; approvals case-by-case.
• Soar Payments — newer player, takes SARMs but tighter underwriting.

Compare detailed approaches in vs Durango, vs Soar, and vs High Risk Pay.

Offshore options

For volume above $500k/month, European or Canadian acquirers enter the picture:

• Emerchantpay (EU) — takes SARMs under controlled conditions. Higher cross-border interchange but lower reserve.
• Paynetics (EU) — high-risk specialty, SARMs eligible.
• Global Payments Canada — approves SARMs for operators with legitimate Canadian structure.

Crypto on-ramp

Not card but relevant. USDC checkout via a gateway like Coinbase Commerce or BitPay converts at 5-12% of card checkout in most SARMs funnels. It's backup volume, not primary.

Rate and reserve reality

Effective rate

For SARMs operators: 4.0-5.5% all-in (interchange + assessments + gateway + PCI + monthly). Under 4.0% is a teaser — read the pricing sheet carefully. See how to read a merchant statement.

Reserve

10-20% rolling for 180 days is typical. Some acquirers use a hybrid: 5% rolling plus a $10-25k upfront reserve. Ask specifically what triggers a reserve increase mid-contract.

Chargeback tolerance

SARMs accounts get watched more closely than nutra. Typical pause trigger: 0.7% monthly ratio. Clean operators run well below 0.3%. Read the chargeback ratio guide.

Volume caps

New SARMs accounts often cap at $50-150k/month for the first 90 days, with lift contingent on clean processing. If your actual volume exceeds the cap, the overflow bounces.

The SKU review problem

Every SARMs ISO runs a SKU review. Some compounds are categorically rejected regardless of marketing:

• MK-677 — rejected by most US acquirers post-2024
• RAD-140 — flagged for enhanced review
• LGD-4033 — similar enhanced review
• Tesofensine, Cardarine — frequently declined

Operators who carry a broad SARMs catalog often run a split strategy: safer compounds on the card-processing account, restricted compounds on crypto-only checkout. This is legal and operationally clean but halves your card conversion on restricted SKUs.

Multi-brand SARMs operators — different calculation

If you run 3+ SARMs brands, the economics change. Separate merchant accounts per brand means:

• N underwriting relationships, each with their own SKU review
• N reserve pools (10-20% each, siloed)
• N chargeback queues to monitor
• N rate negotiations
• Per-brand fraud — one brand's issue doesn't spread

A parent merchant account with brand-preserved descriptors changes the model:

• One underwriting relationship, one SKU review
• Consolidated reserve (usually lower percentage across aggregate volume)
• One dispute team
• Concentration risk — one bad brand affects the portfolio reserve

The structural tradeoff is usually worth it above 3 brands. See the SARMs operator playbook for the full comparison.

What to check before signing

• Contract term + ETF — 2-3 year terms with $250-500 ETF are standard. Negotiate.
• Chargeback tolerance in writing — not "we're flexible." Get the specific ratio at which the account pauses.
• Reserve release conditions — define what "clean processing" means. 180 days at what ratio?
• SKU approval process — can you add new SKUs without re-underwriting? What triggers re-review?
• Descriptor control — can you run a dynamic descriptor per brand/product?

What not to do

• Don't apply to Stripe claiming you're selling "research supplements." The automated crawler catches SARMs-adjacent language within 48 hours.
• Don't split one brand across three merchant accounts to avoid volume caps — acquirers detect this via shared IPs, descriptors, and beneficial ownership.
• Don't assume crypto solves the card problem — SARMs crypto checkout converts at 5-15% of card checkout, so crypto-only kills growth.
• Don't pay a "merchant rescue consultant" who promises Stripe approval for SARMs. It doesn't exist.

What to do next

If single-brand and under $100k/month: apply to EasyPayDirect + Durango + Corepay in parallel. Compare actual contracts. Choose based on reserve + chargeback policy + ETF, not on setup fee waivers.

If multi-brand: the parent-account model usually compresses 3+ brands into one underwriting relationship. Our 12-question application gives us enough to assess whether your portfolio fits.

If you're already on MATCH from a prior closure: read the MATCH playbook first. SARMs + MATCH narrows the pool to a handful of specialist offshore acquirers.